2019-nCoV Spike protein RBD  (L452R, T478K), HRP conjugated (C19SD-G231FD)

2019-nCoV Spike protein RBD (L452R, T478K), HRP conjugated (C19SD-G231FD)

  • $100.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description: Recombinant 2019-nCoV Spike protein S1 subunit, RBD (L452R, T478K) (319-541) was expressed in CHO cells using a C-terminal his tag, and then conjugated to Horse peroxidase (HRP).

Species: SARS-CoV-2

Tag: HIS tag

Expression System: CHO Cells

Sequence: 319-541

Genbank Number: MN908947

 

Activity:  Binding ability measured in a functional ELISA. 2019-nCoV RBD (L452R, T478K) binds to immobilized human ACE2 (19-740) protein (A51C2-G341F).

Storage and Stability:  Store product at –20oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Gene Aliases : 2019-nCoV RBD, SARS-CoV-2 spike RBD, novel coronavirus spike RBD, nCoV spike RBD, delta

Scientific Background: The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). SARS-CoV-2 variant B.1.617.2 (delta) carrying mutations L452R, T478K in the RBD has been reported to severely affect regions of India (2). This variant has been shown to have higher transmissibility and pathogenicity in hamster model, thus raising concerns about the neutralizing capability of vaccines. As new variants emerge, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).

References : 

  1. Lan J, et al: Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235.
  2. Chakrabory C, et al: Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Medical Virology, 2020; doi: https://doi.org/10.1002/rmv.2270
  3. Pragya D, et al: Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. bioRxiv 2021, doi: https://doi.org/10.1101/2021.05.12.443645

Product Sheets (By Lot #) :

J4076-11